Actualizado
Reviewed
Jun. 03, 2021
Appendix A: Key to Acronyms
General Terms
Acronym | Definition |
---|---|
17-BMP | beclomethasone 17-monopropionate |
ACTG | AIDS Clinical Trials Group |
ACA | Affordable Care Act |
ADAP | AIDS drug assistance program |
AE | adverse events |
Ag/Ab | antigen/antibody |
Al | aluminum |
ALT | alanine aminotransferase |
ARDENT | ACTG A5257 trial |
ART | antiretroviral therapy |
ARTAS | Anti-Retroviral Treatment and Access to Services |
ARV | antiretroviral |
AST | aspartate aminotransferase |
AUC | area under the curve |
AUD | alcohol use disorder |
AUDIT-C | Alcohol Use Disorders Identification Test-Consumption |
AV | atrioventricular |
AWP | average wholesale price |
AYA | adolescents and young adults |
BID | twice daily |
BMD | bone mineral density |
BUN | blood urea nitrogen |
Ca | calcium |
CaCO3 | calcium carbonate |
CBC | complete blood count |
CCB | calcium channel blockers |
CD4 | CD4 T lymphocyte |
CDC | Centers for Disease Control and Prevention |
CI | confidence interval |
Cl | chloride |
Cmax | maximum plasma concentration |
Cmin | minimum plasma concentration |
CMV | cytomegalovirus |
CNS | central nervous system |
COC | combined oral contraceptive |
CPAPA | Common Patient Assistance Program Application |
CPK | creatine phosphokinase |
Cr | creatinine |
CrCl | creatinine clearance |
CSF | cerebrospinal fluid |
CV | cardiovascular |
CVD | cardiovascular disease |
CYP | cytochrome P450 |
CYP3A4 | cytochrome P450 3A4 |
D:A:D | Data Collection on Adverse Events of Anti-HIV Drugs |
D/M | dual/mixed |
DAA | direct-acting antiviral |
DHA | dihydroartemisinin |
DILI | drug-induced liver injury |
DMPA | depot medroxyprogesterone acetate |
DOT | directly observed therapy |
EBV | Epstein-Barr virus |
ECG | electrocardiogram |
ECHO | Evidence for Contraceptive Options in HIV |
eGFR | estimated glomerular filtration rate |
FDA | Food and Drug Administration |
FDC | fixed-dose combination |
Fe | iron |
FUL | federal upper limit |
GAHT | gender-affirming hormone therapy |
GHB | gamma-hydroxybutyrate |
GI | gastrointestinal |
gp | glycoprotein |
GS | Gilead Sciences |
HAD | HIV-associated dementia |
HAND | HIV-associated neurocognitive disorder |
HAV | hepatitis A virus |
HBcAb | hepatitis B core antibody |
HBeAg | hepatitis B e antigen |
HBsAb | hepatitis B surface antibody |
HBsAg | hepatitis B surface antigen |
HBV | hepatitis B virus |
HCV | hepatitis C virus |
HD | hemodialysis |
HDL | high-density lipoprotein |
HHS | Department of Health and Human Services |
HIV | human immunodeficiency virus |
HIV RNA | HIV viral load |
HIV-1 | human immunodeficiency virus type 1 |
HIV-2 | human immunodeficiency virus type 2 |
HLA | human leukocyte antigen |
HMG-CoA | hydroxy-methylglutaryl-coenzyme A |
HRSA | Health Resources and Services Administration |
HR | hazard ratio |
HRT | hormone replacement therapy |
hs-CRP | high-sensitivity C-reactive protein |
HSR | hypersensitivity reaction |
HTLV-1 | human T-lymphotropic virus-1 type I |
IL | interleukin |
IAS-USA | International AIDS Society-USA |
IC50 | inhibitory concentration |
IN | integrase |
IM | intramuscular |
INR | international normalized ratio |
INSTI | integrase strand transfer inhibitor |
IRIS | immune reconstitution inflammatory syndrome |
IPT | isoniazid preventative therapy |
ISR | injection site reactions |
IUD | intrauterine device |
K | potassium |
LAI | long-acting injectable |
LDL | low-density lipoprotein |
LGBTQ | lesbian, gay, bisexual, transgender, or queer |
LLOD | lower limits of detection |
LTBI | latent tuberculosis infection |
MAC | Mycobacterium avium complex |
MAT | medication-assisted treatment |
MATE | multidrug and toxin extrusion transporter |
MDR-TB | multidrug-resistant tuberculosis |
MDMA | methylenedioxymethamphetamine |
MEMS | Medication Event Monitoring System |
MET | motivational enhancement therapy |
MDR | multidrug-resistant |
Mg | magnesium |
MI | motivational interviewing |
MHC | major histocompatibility complex |
MI | myocardial infarction |
MPA | medroxyprogesterone acetate |
MSM | men who have sex with men |
MTR | multi-tablet regimen |
NA-ACCORD | North American AIDS Cohort Collaboration on Research and Design |
NIH | National Institutes of Health |
NNRTI | non-nucleoside reverse transcriptase inhibitor |
NRTI | nucleoside/nucleotide reverse transcriptase inhibitor |
NTD | neural tube defect |
OARAC | Office of AIDS Research Advisory Council |
OAT | opioid agonist therapy |
OATP | organic anion-transporting polypeptide |
OCT2 | organic cation transporter 2 |
OH-itraconazole | active metabolite of itraconazole |
OI | opportunistic infection |
ONDCP | Office of National Drug Control Policy |
OR | odds ratio |
OTP | opioid treatment program |
OUD | opioid use disorder |
P-gp | p-glycoprotein |
PAH | pulmonary arterial hypertension |
The Panel | The Panel on Antiretroviral Guidelines for Adults and Adolescents |
PBM | pharmacy benefit manager |
PCP | Pneumocystis jirovecii pneumonia |
PCR | polymerase chain reaction |
PDE5 | phosphodiesterase type 5 |
PHQ-2 | Patient Health Questionnaire-2 |
PEP | post-exposure prophylaxis |
PI | protease inhibitor |
PI/c | cobicistat-boosted protease inhibitor |
PI/r | ritonavir-boosted protease inhibitor |
PK | pharmacokinetic |
PO | orally |
PPI | proton pump inhibitor |
PR | protease |
PrEP | pre-exposure prophylaxis |
PTH | parathyroid hormone |
QTc | QT corrected for heart rate |
REPC | Retention through Enhanced Personal Contact |
RNA | ribonucleic acid |
RR | relative risk |
RT | reverse transcriptase |
RWHAP | Ryan White HIV/AIDS Program |
SAMHSA | Substance Abuse and Mental Health Services Administration |
SMR | sexual maturity rating |
SPT | skin patch test |
SSRI | selective serotonin reuptake inhibitor |
STI | sexually transmitted infection |
STR | single-tablet regimen |
STaR trial | Single-Tablet Regimen trial |
SUD | substance use disorder |
TasP | treatment as prevention |
TB | tuberculosis |
TCA | tricyclic antidepressant |
TDM | therapeutic drug monitoring |
THRIVE | Targeting HIV Retention and Improved Viral Load Through Engagement |
TID | three times a day |
UGT | uridine diphosphate glucuronosyltransferase |
ULN | upper limit of normal |
USTS | U.S. Transgender Survey |
UW | University of Washington |
UGT1A1 | uridine diphosphate glucuronosyltransferase 1A1 |
VPA | valproic acid |
WAC | wholesale acquisition cost |
WBC | white blood cell |
WHO | World Health Organization |
WPATH | World Professional Association for Transgender Health |
XDR | extensively drug-resistant |
XR | extended release |
Zn | zinc |
Download Guidelines
- Section OnlyPDF (264.28 KB)
- Full GuidelinePDF (5.07 MB)
- Recommendations OnlyPDF (229.24 KB)
- Tables OnlyPDF (939.48 KB)